Opiant Pharmaceuticals to Report Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 12, 2020
Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) will report its Q3 2020 financial results on November 12, 2020, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) will report its Q3 2020 financial results on November 12, 2020, after market close. The management team will host a conference call at 4:30 p.m. ET on the same day, accessible by dial-in and webcast. Opiant is focused on developing medications for addictions and drug overdoses, having created the NARCAN® Nasal Spray.
Positive
- Company is developing medicines for addictions and overdoses, indicating potential market growth.
- Upcoming financial results presentation may provide insights into company performance.
Negative
- None.
Details
News Market Reaction – OPNT
The recorded move for OPNT in the trading session of this news was -2.73%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SANTA MONICA, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report its third quarter 2020 financial results after the financial markets close on Thursday November 12, 2020.
The Company’s management team is scheduled to host a conference call and webcast at 4:30 p.m. ET on Thursday November 12, 2020. To access the call, please dial 877-407-0792 in the U.S. or 201-689-8263 outside the U.S. and provide the conference ID number: 13712206. To access the live webcast, please go to the investors section of Opiant’s website at http://ir.opiant.com/. Following the live webcast, an archived version of the call will be available on the website.
| Thursday November 12 @ 4:30 pm ET | |
| Domestic: International: Conference ID: Webcast: | 877-407-0792 201-689-8263 13712206 http://ir.opiant.com/ |
About Opiant Pharmaceuticals, Inc.
Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose.
For more information visit: www.opiant.com.
Investor Relations Contacts:
Ben Atkins
VP of Corporate Communications and Investor Relations
batkins@opiant.com
(310) 598-5410
Dan Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com
(617) 430-7576
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.